Clinical trial

Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy

NCT07596524

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

OTHER · Unmapped registry intervention Observation Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy

Design: OBSERVATIONAL · Status: NOT YET RECRUITING · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeOBSERVATIONAL

Start date2026-07-01

PhaseN/A

Conditions

Lung Cancer (NSCLC)unresolved

Interventions

ObservationOTHER

Sponsors & collaborators

Cancer Institute and Hospital, Chinese Academy of Medical Scienceslead sponsor

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07596524 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.